About Novaremed
Novaremed is a company based in Petah Tikva (Israel) founded in 2008 by Eliahu Kaplan.. Novaremed has raised $65.95 million across 5 funding rounds from investors including Global Emerging Markets. Novaremed has completed 1 acquisition, including Metys Pharmaceuticals. Novaremed offers products and services including NRD.E1, MP-101, and MP-103. Novaremed operates in a competitive market with competitors including Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.
- Headquarter Petah Tikva, Israel
- Founders Eliahu Kaplan
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Novaremed Ag
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$65.95 M (USD)
in 5 rounds
-
Latest Funding Round
$50 M (USD), Series B
Jan 28, 2021
- Investors
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Novaremed
Novaremed offers a comprehensive portfolio of products and services, including NRD.E1, MP-101, and MP-103. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Non-opioid treatment for painful diabetic peripheral neuropathy.
Combination drug for preventing chemotherapy-induced peripheral neuropathy.
Oral treatment for various forms of peripheral neuropathy.
Funding Insights of Novaremed
Novaremed has successfully raised a total of $65.95M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $50.0M
-
First Round
First Round
(01 Apr 2018)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Series B - Novaremed | Valuation | Global Emerging Markets |
|
| Sep, 2020 | Amount | Series A - Novaremed | Valuation |
investors |
|
| Sep, 2019 | Amount | Series A - Novaremed | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Novaremed
Novaremed has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Global Emerging Markets. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this private equity firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Novaremed
Novaremed has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Metys Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Drugs for chemotherapy-induced peripheral neuropathy and CNS disorders are developed.
|
2013 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Novaremed
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Novaremed Comparisons
Competitors of Novaremed
Novaremed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| domain | founded_year | HQ Location |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| domain | founded_year | HQ Location |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for pain management are developed with abuse-deterrent designs.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Novaremed
Frequently Asked Questions about Novaremed
When was Novaremed founded?
Novaremed was founded in 2008 and raised its 1st funding round 10 years after it was founded.
Where is Novaremed located?
Novaremed is headquartered in Petah Tikva, Israel. It is registered at Petah Tikva, Central District, Israel.
Who is the current CEO of Novaremed?
Eliahu Kaplan is the current CEO of Novaremed. They have also founded this company.
Is Novaremed a funded company?
Novaremed is a funded company, having raised a total of $65.95M across 5 funding rounds to date. The company's 1st funding round was a Series A of $2.63M, raised on Apr 01, 2018.
What does Novaremed do?
Novaremed was founded in 2008 in Petah Tikva, Israel, and operates in the biotechnology sector focused on neuropathic pain therapies. A proprietary library of small molecules, derived from a biological substance with anti-inflammatory properties, is utilized to build its drug pipeline. The lead candidate, NRD135S-E1, a first-in-class tyrosine kinase modulator, is currently undergoing phase 2 clinical trials through a novel mechanism of action.
Who are the top competitors of Novaremed?
Novaremed's top competitors include Flexion Therapeutics, Cara Therapeutics and Satsuma Pharmaceuticals.
What products or services does Novaremed offer?
Novaremed offers NRD.E1, MP-101, and MP-103.
How many acquisitions has Novaremed made?
Novaremed has made 1 acquisition, including Metys Pharmaceuticals.
Who are Novaremed's investors?
Novaremed has 1 investor. Key investors include Global Emerging Markets.